Lund, Sweden, 27 June 2024 - Transient Pharma AB has secured 16 million SEK in funding from SmiLe Inject Capital AB and private investors to advance the pre-clinical development of their novel drug…

Lund, Sweden – SmiLe is very pleased to announce the addition of Transient Pharma AB to our incubator program. Transient Pharma is dedicated to the development of innovative systemic…

The development of a new treatment strategy for bacterial infections and sepsis is being led by researchers at Lund University. In a study the researchers demonstrate how they, by mimicking a…